On June 25, 2025, analyst Jason Kolbert from D. Boral Capital reaffirmed a "Buy" rating for Immunic (IMUX, Financial), maintaining the previously set price target of $10.00 USD. This decision reflects the analyst's continued confidence in the company's potential and market position.
Immunic (IMUX, Financial), a company listed on the NASDAQ exchange, has seen no change in its price target or rating, as both remain consistent with prior assessments. The analyst's unchanged stance indicates steady expectations for the company's future performance.
The maintained price target of $10.00 suggests that the analyst believes Immunic (IMUX, Financial) has the potential for positive growth or stability at its current market valuations. Investors and market participants may continue to monitor the stock for any future developments or changes in analyst evaluations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Immunic Inc (IMUX, Financial) is $12.33 with a high estimate of $28.00 and a low estimate of $4.00. The average target implies an upside of 1,642.00% from the current price of $0.71. More detailed estimate data can be found on the Immunic Inc (IMUX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Immunic Inc's (IMUX, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
